March 06, 2026 — Suresnes, France & Brisbane, California, USA
Global pharmaceutical group Servier and oncology-focused biotech Day One Biopharmaceuticals have announced a definitive agreement under which Servier will acquire Day One Biopharmaceuticals in an all-cash transaction valued at approximately $2.5 billion. The acquisition aims to strengthen Servier’s rare oncology portfolio and expand its pipeline of targeted cancer therapies, particularly for pediatric cancers and other high-unmet-need indications. The deal represents another strategic step in Servier’s long-term ambition to become a global leader in oncology innovation, while accelerating the development of therapies designed to improve outcomes for patients with life-threatening diseases.
Strategic Acquisition Strengthens Rare Oncology Pipeline
Under the terms of the agreement, Servier will launch a cash tender offer to acquire all outstanding shares of Day One Biopharmaceuticals for $21.50 per share, representing a total equity value of approximately $2.5 billion. The offer price reflects a significant premium over Day One’s recent trading value, highlighting Servier’s confidence in the company’s oncology research pipeline and scientific capabilities. The transaction remains subject to customary closing conditions, including shareholder approval and regulatory clearances, and is expected to close during the second quarter of 2026.
The acquisition is strategically designed to reinforce Servier’s global position in targeted oncology therapies, an area the company has prioritized within its 2030 strategic vision. By integrating Day One’s scientific expertise with Servier’s global research and commercialization capabilities, the combined organization will be better positioned to accelerate innovation in rare cancers and expand access to targeted treatments worldwide. Servier leadership emphasized that the transaction aligns closely with the company’s commitment to investing in scientific breakthroughs capable of delivering meaningful benefits for patients living with rare and difficult-to-treat cancers.
Focus on Pediatric Cancer Innovation
Advertisement
Day One Biopharmaceuticals was founded with the mission of addressing the critical shortage of therapeutic development for pediatric cancers, an area that historically has received limited investment compared with adult oncology. The company focuses on developing targeted therapies designed to treat life-threatening cancers affecting patients of all ages, with particular emphasis on children and adolescents. By acquiring Day One, Servier gains access to innovative drug development programs targeting pediatric low-grade glioma and other rare tumor types, significantly strengthening its oncology pipeline across multiple stages of clinical development.
The acquisition positions Servier to become a global leader in treatments for pediatric low-grade glioma, one of the most common brain tumors affecting children. It also enables the company to expand its broader oncology pipeline, which includes programs spanning early-stage research through Phase 3 clinical trials. Industry experts note that partnerships and acquisitions like this are increasingly common in the biopharmaceutical sector, where larger pharmaceutical organizations leverage the scientific innovation and specialized expertise of smaller biotechnology firms to accelerate the development of new therapies.
Advancing Global Oncology Innovation
Servier is an independent international pharmaceutical group headquartered in France with a strong global presence and medicines distributed in more than 130 countries worldwide. The company has identified oncology and neurology as its key innovation areas and currently invests approximately 20% of its brand-name medicine revenue into research and development. Through strategic acquisitions such as the purchase of Day One Biopharmaceuticals, Servier aims to expand its global oncology leadership and accelerate the discovery of targeted therapies for patients facing rare cancers and neurological diseases.
For Day One Biopharmaceuticals, joining Servier offers an opportunity to scale its scientific discoveries globally and bring its targeted cancer therapies to a broader patient population. Company leadership noted that Servier’s longstanding commitment to rare diseases and oncology research makes it an ideal partner for advancing Day One’s mission of transforming cancer treatment starting from the earliest stages of diagnosis and therapy development.
As the global pharmaceutical industry increasingly prioritizes precision medicine and targeted cancer therapies, strategic acquisitions such as this reflect a broader trend toward collaboration between innovative biotechnology companies and established pharmaceutical organizations. By combining research capabilities, clinical development expertise, and global commercialization infrastructure, these partnerships play a critical role in accelerating the development of next-generation oncology therapies designed to address some of the most urgent unmet medical needs in modern healthcare.
z
Source: Day One Biopharmaceuticals press release
